Recruitment and Development of R&D Personnel and Flexible Organizational Management
First written in FY2016. 3 of 7 entries say "Restated". Latest entry: FY2026.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2026: 3 of 34 companies on the "Worse" side.
2 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The Group has adopted “People's growth equals the Company's growth: maximizing human resources and organizational capabilities” as its medium- to long-term management strategy and aims for sustainable growth and enhanced corporate value. It recognizes that realizing this strategy requires securing and developing personnel with diverse areas of expertise and building an organizational foundation that enables each employee to maximize their capabilities.」
The previous focus on securing R&D personnel and developing the necessary work environment has broadened into a human capital strategy covering the recruitment of specialists and global talent, next-generation leadership development, digital skills training, diverse working styles, and employee engagement. - 2026-06-03WorsenedGeneral Meetings of Shareholders
「Number of employees 54; change from the end of the previous consolidated fiscal year: down 4」
The consolidated number of employees decreased by 4 from the end of the previous fiscal year to 54. - FY2025RestatedAnnual report
「The Group considers it essential to secure researchers familiar with each business and personnel capable of driving projects. To improve R&D efficiency, it will create an environment suited to R&D from both the physical and non-physical perspectives and seek to maximize corporate value.」
The Group continues to identify securing researchers and personnel capable of driving projects, developing the R&D environment and flexible organizational management as challenges. - FY2024WorsenedAnnual report
「In the cosmetics-related business, concentrating investment on the antibody-related business caused a personnel shortage that prevented domestic and overseas sales activities. Revenue was ¥3.851 million, down 4.2% year on year.」
A personnel shortage resulting from the concentration of investment on the antibody-related business constrained domestic and overseas sales activities in the cosmetics business, leading to lower revenue. - FY2019RestatedAnnual report
「The Group considers it essential to secure researchers familiar with each business and personnel capable of driving projects. To improve R&D efficiency, it will create an environment suited to R&D from both the physical and non-physical perspectives and seek to maximize corporate value.」
The Group continues to secure researchers and personnel capable of driving projects and develop an environment suited to R&D. - FY2017RestatedAnnual report
「The Group considers it essential to secure researchers familiar with each business and personnel capable of driving projects. To improve R&D efficiency, it will create an environment suited to R&D from both the physical and non-physical perspectives and seek to maximize corporate value.」
The Group continues to secure researchers and personnel capable of driving projects and develop its R&D environment. - FY2016First statedAnnual report
「As part of this approach, the Company will create an environment suited to R&D from both the physical and non-physical perspectives to improve R&D efficiency.」
The Company identifies securing researchers and personnel capable of driving projects as a challenge and plans to develop its R&D environment.